MedTrace Logo

HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis

NCT00305539 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2012-07-10

No results posted yet for this study

Summary

Hypothesis: In giant cell arteritis (GCA), a short initial treatment with anti-TNF may allow a faster decrease of steroids dosage and therefore avoid some of the adverse events of steroids.

Conditions

  • Giant Cell Arteritis

Interventions

DRUG

adalimumab

40 mg sc / for 3 months

DRUG

placebo

placebo

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Xavier Mariette, MD, PhD · Hôpital Bicêtre, APHP, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00305539 on ClinicalTrials.gov